SCHEMBL4055642

SCHEMBL4055642

FC(F)(F)c1cccc(-c2nc3ncc(Br)cc3[nH]2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
THRB P10828 1/20 0.53
PKM P14618 1/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
STAT6 P42226 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
HIF1A Q16665 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HSD17B10 Q99714 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057030 0.85 SCN2A (0.53) AURKASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL4058129 0.83 AURKA (0.56) AURKASMN1; SMN2CYP1A2CYP3A4KDM4E
SCHEMBL4052740 0.82 SMN1; SMN2 (0.49) AURKASMN1; SMN2NPC1HPGDHTT
SCHEMBL4058461 0.82 SCN2A (0.56) AURKASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL4059653 0.81 HTT (0.55) AURKASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL1667430 0.81 AURKA (0.68) AURKASMN1; SMN2MEN1NPC1ALDH1A1
SCHEMBL4058364 0.80 AURKA (0.56) AURKASMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL4054040 0.80 AURKA (0.60) AURKASMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL13607863 0.80 CYP1A2 (0.53) SMN1; SMN2CYP1A2CYP3A4CYP2C9KDM4E
SCHEMBL4055581 0.79 CYP1A2 (0.47) AURKASMN1; SMN2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885SMN1; SMN2 4289/4885CYP1A2 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.